



(51) **International Patent Classification:**
G01N 33/576 (2006.01) **G01N 33/68** (2006.01)
C12Q 1/70 (2006.01)

(21) **International Application Number:**
PCT/EP2010/067252

(22) **International Filing Date:**
11 November 2010 (11.11.2010)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
61/261,324 14 November 2009 (14.11.2009) US

(71) **Applicant (for all designated States except US): F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only): CHIU, Shu-Hui** [US/US]; 10310 Tula Lane, Cupertino, California 95014 (US). **ZHU, Yonghong** [CN/US]; 707 Continental Circle, #1632, Mountain View, California 94040 (US).

(74) **Agent: HALBIG, Dirk**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title: BIOMARKERS FOR PREDICTING RAPID RESPONSE TO HCV TREATMENT**




FIG. 1

(57) **Abstract:** The present invention relates to biomarkers that are useful for predicting the response of hepatitis C virus infected patients to pharmacological treatment.